Unlike a prospective trial of patients with polycythemia vera, ruxolitinib, a JAK2 inhibitor, did not show better efficacy than the best available therapy in HU‐resistant or ‐intolerant patients with ET in the MAJIC‐ET trial.14 The gene discussed is JAK2; the disease is essential thrombocythemia.